InvestorsHub Logo
Followers 87
Posts 6693
Boards Moderated 1
Alias Born 09/18/2009

Re: TankTheFrank post# 41019

Thursday, 11/09/2023 5:59:54 PM

Thursday, November 09, 2023 5:59:54 PM

Post# of 42926
Well, as far as the Novavax news, we have to remember that they were reporting for the 3rd Quarter. Their EU approval was dated Oct 31st. The US EUA was approved Oct 3rd. I was just hoping to pick up some hints from the 'management discussion' or 'subsequent events' portions of the filing, which is where they mentioned a prototype covid vaccine.

Even if we release our Q2 and Q3 10-Q's next week, I will look at Q3's 'management discussion' and 'subsequent events' portions of the filing. I still think a business arrangement of some sort with Novavax will yield the best revenue-related news we could hope for. And I don't think management is as concerned as they previously were about funds.

So maybe we will hear about a Priority Review Voucher associated with approval of lenz to treat CMML. I just saw a PRV sold for $105M.

Keep in mind that the first recall of our loaned shares caused a massive increase in share price without any other news, except for announcing an accumulation of a 50% ownership stake by Shkreli, which increased to 70%. I think we could announce a 92% ownership stake, if management has 110M of the 119M shares they have issued.

I just hope that we don't file another NT10-Q for the 3rd quarter. But I agree with you that we need to see "visible action occurring." So if another NT10-Q is necessary until we get regulatory approval, or whatever is necessary, we'll just have to deal with it, which I don't want to think about anymore than management does.